Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Suzuki T, Matsuura K, Sobue S, Kato D, Hayashi K, Kondo H, Anbe K, Mizoshita T, Okayama K, Okumura F, Kimura Y, Ozasa A, Inada H, Tokunaga T, Narahara S, Kawamura H, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y

Open source

DOI: 10.1111/hepr.14189
Published: 2025 Jun
Container: Hepatology research : the official journal of the Japan Society of Hepatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/hepr.14189,
  title = {Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.},
  author = {Suzuki T and Matsuura K and Sobue S and Kato D and Hayashi K and Kondo H and Anbe K and Mizoshita T and Okayama K and Okumura F and Kimura Y and Ozasa A and Inada H and Tokunaga T and Narahara S and Kawamura H and Fujiwara K and Nojiri S and Kataoka H and Tanaka Y},
  year = {2025},
  journal = {Hepatology research : the official journal of the Japan Society of Hepatology},
  doi = {10.1111/hepr.14189},
  url = {https://doi.org/10.1111/hepr.14189}
}

RIS

TY  - JOUR
TI  - Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
AU  - Suzuki T
AU  - Matsuura K
AU  - Sobue S
AU  - Kato D
AU  - Hayashi K
AU  - Kondo H
AU  - Anbe K
AU  - Mizoshita T
AU  - Okayama K
AU  - Okumura F
AU  - Kimura Y
AU  - Ozasa A
AU  - Inada H
AU  - Tokunaga T
AU  - Narahara S
AU  - Kawamura H
AU  - Fujiwara K
AU  - Nojiri S
AU  - Kataoka H
AU  - Tanaka Y
PY  - 2025
JO  - Hepatology research : the official journal of the Japan Society of Hepatology
DO  - 10.1111/hepr.14189
UR  - https://doi.org/10.1111/hepr.14189
ER  -

APA

T, S., K, M., S, S., D, K., K, H., H, K., K, A., T, M., K, O., F, O., Y, K., A, O., H, I., T, T., S, N., H, K., K, F., S, N., H, K., & Y, T. (2025). Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.. Hepatology research : the official journal of the Japan Society of Hepatology. https://doi.org/10.1111/hepr.14189

Source records

pubmed · retrieved 2026-09-27T01:15:54.210Z